Nora Cothran
Optometrist · Largo, FLNPI 1467882050
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $323,635 of the $504,767 with a category attached, or 64.1%. 28 manufacturers reported payments, led by AbbVie at 43.5% of the total. 2025 is the largest year on record at $171,555, more than ten times the $4,684 reported in 2019. Among optometrist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,058 payments — averaging $477.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$219K
- Bausch & Lomb Americas Inc.$159K
- Alcon$79K
- Aerie Pharmaceuticals, Inc.$23K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
- Alcon Research LLC$6K
- plus $8K from 22 others
Across 1 payment — averaging $12,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$13K
What the payments were for
- Consulting fees$70,35614%
- Speaking & faculty fees$323,63564%
- Travel & lodging$83,77417%
- Food & beverage$26,8535%
- Education$180%
- Entertainment$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 470 | $219,324 |
| Bausch & Lomb Americas Inc. | 211 | $158,593 |
| Alcon | 154 | $79,189 |
| Aerie Pharmaceuticals, Inc. | 71 | $23,269 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $9,917 |
| Alcon Research LLC | 2 | $6,275 |
| Glaukos Corporation | 16 | $2,732 |
| Sight Sciences, Inc. | 18 | $1,637 |
| Sun Pharmaceutical Industries Inc. | 14 | $611 |
| Amgen(2 entities) | 10 | $450 |
| Oyster Point Pharma, Inc. | 9 | $434 |
| Harrow Eye, LLC | 14 | $426 |
| Dompe US, Inc. | 9 | $379 |
| NEW World Medical,inc. | 3 | $317 |
| Novartis | 9 | $227 |
| Astellas Pharma US Inc | 1 | $189 |
| Ivantis, Inc | 2 | $138 |
| Optos, Inc. | 1 | $130 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $97 |
| Kala Pharmaceuticals, Inc. | 4 | $79 |
| Lensar, Inc. | 1 | $78 |
| Regeneron Healthcare Solutions, Inc. | 3 | $67 |
| Tarsus Pharmaceuticals, Inc. | 2 | $59 |
| Shire North American Group Inc | 2 | $47 |
| Thea Pharma Inc. | 2 | $38 |
| Genentech USA, Inc. | 1 | $24 |
| Akorn, Inc. | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$141,796
- VYZULTA$84,767
- Rocklatan$84,482
- Rhopressa$78,761
- MIEBO$62,172
- LUMIGAN$54,288
- XIIDRA$39,737
- VUITY$26,925
- XEN GLAUCOMA TREATMENT SYSTEM$21,020
- LOTEMAX SM$18,657
- COMBIGAN$15,880
- SIMBRINZA$14,452
- TRYPTYR$14,187
- ALPHAGAN P$6,635
- RESTASIS MULTIDOSE$1,275
- iDose$1,000
- RADIUS$1,000
- OMNI(R) SURGICAL SYSTEM (US)$876
- BLINK NUTRITEARS$600
- Hydrus Microstent$374
How this compares
$504,767 in reported general payments places this provider in the 95th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 495 | $380,153 |
| LumiganBimatoprost | 498 | $302,596 |
| RestasisCyclosporine | 214 | $288,771 |
| VyzultaLatanoprostene Bunod | 323 | $232,354 |
| MieboPerfluorohexyloctane/Pf | 104 | $106,148 |
| RhopressaNetarsudil Mesylate | 161 | $104,017 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 234 | $91,957 |
| CombiganBrimonidine Tartrate/Timolol | 114 | $61,782 |
| XiidraLifitegrast | 22 | $43,789 |
| Alphagan PBrimonidine Tartrate | 28 | $23,324 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 103 | $23,046 |
| Cyclosporine | 32 | $20,548 |
| LotemaxLoteprednol Etabonate | 28 | $13,570 |
| Latanoprost | 958 | $12,449 |
| Lotemax SmLoteprednol Etabonate | 37 | $10,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $219,324 | $676,474854 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $23,269 | $484,169656 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo, Xiidra | $158,593 | $382,291449 claims |
| AlconSimbrinza | $79,189 | $91,957234 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Lotemax Sm, Loteprednol Etabonate | $9,917 | $29,690100 claims |
| NovartisTravatan Z | $227 | $6,91911 claims |
| Akorn, Inc.Zioptan | $23 | $6,18714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Largo
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$553K
- Michael SluskyNorth Port$384K
- Katie SpearDefuniak Springs$361K
- Karen HoffmanOrange Park$282K
- Ashley RothMiami Beach$261K
- Jessica SteenDavie$256K
- Mark DunbarMiami$236K
- Robert DavisPembroke Pines$217K
- Julie RodmanFort Lauderdale$205K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.